Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study
Open Access
- 24 May 2023
- journal article
- research article
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 35 (6) , 263-271
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 24 references indexed in Scilit:
- Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de CardiologíaRevista Espanola de Cardiologia, 2016
- Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPARRevista Espanola de Cardiologia, 2016
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic InterventionsJAMA, 2016
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasEuropean Heart Journal, 2016
- Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingSpringerPlus, 2016
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin IntoleranceJACC, 2014
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With HypercholesterolemiaJAMA, 2014
- A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaNew England Journal of Medicine, 2014
- Management of dyslipidaemiaHeart, 2004